We have previously demonstrated that follicles ≤11 mm diameter from women undergoing IVF contain higher concentrations of gonadotrophin surge attenuating factor (GnSAF) bioactivity than large follicles from the same ovaries. METHODS: To determine whether this finding is relevant to spontaneous cycles, follicular fluid aspirated from 37 follicles between 3 and 25 mm in diameter from 14 pairs of ovaries from regularly cycling women undergoing total abdominal hysterectomy and bilateral salpingoophorectomy for benign gynaecological disease was pooled into size categories (3 ⍣ 4, 5 ⍣ 6, 7 ⍣ 8, 9 ⍣ 10, 11 ⍣ 12, 14 ⍣ 15, 18 and 25 mm). These pools were bioassayed for GnSAF and inhibin-A, inhibin-B and activin-A concentrations were determined. RESULTS: Follicles of 5 ⍣ 6 mm diameter contained the highest concentrations of GnSAF bioactivity (reducing GnRH-induced LH secretion to 38 ⍨ 8% of control, P < 0.001), while those of 25 mm diameter contained one quarter of this concentration (reducing GnRH-induced LH secretion to 72 ⍨ 2% of control, P < 0.05). GnSAF bioactivity was closely related to follicle size (r ⍧ -0.836, P < 0.01), but not to inhibin-A, inhibin-B or activin-A concentrations. CONCLUSIONS: The finding that small follicles contain high concentrations of GnSAF bioactivity, which fall as folliculogenesis progresses during spontaneous cycles, support the hypothesis that GnSAF has a role in preventing the premature onset of the LH surge in women.
Introduction
data from unstimulated pigs and cows show that GnSAF activity is present in follicular fluid, and in pigs declined with Gonadotrophin surge-attenuating factor/inhibiting factor increasing size beyond a peak of activity in follicles between (GnSAF) has the specific biological effect of reducing pituitary 7 and 8 mm diameter (Koppenaal et al., 1992; Kita et al., responsiveness to gonadotrophin-releasing hormone (GnRH) 1994), it is important to confirm such findings in humans. For without affecting constitutive LH or FSH secretion. The
GnSAF to have a role in the timing of the LH surge, its production of GnSAF by the ovary in various species is production during the follicular phase would need to be stimulated by FSH both in vivo and in vitro (Fowler and regulated and co-ordinate with folliculogenesis. Templeton, 1996) . Despite its obvious potential in reproductive
In this paper we present evidence that in the spontaneously technologies, GnSAF remains enigmatic: three different cycling women, GnSAF bioactivity is inversely related to putative GnSAF amino acid sequences have been published follicle size, with direct implications for the role of GnSAF (Tio et al., 1994; Danforth and Cheng, 1995; Pappa et al., in the regulation of the ovarian cycle. 1999) and to date none has been confirmed as GnSAF.
We have previously demonstrated that GnSAF bioactivity is not an artefact of ovarian stimulation protocols since it is Materials and methods also found in spontaneous cycle follicular fluid and serum (Byrne et al., 1993) . Although we know that Follicular fluid from unstimulated ovaries small follicles contain much greater concentrations of GnSAF Ovaries were obtained from women undergoing oophorectomy for bioactivity than large follicles , the latter non-ovarian gynaecological pathology. Approval for the current study data were based upon follicular fluid aspirated from IVF was granted by the local ethics committees of the hospitals concerned follicles and might possibly be an artefact of the stimulation and each woman gave informed consent. Details of menstrual cycle history (cycle length, duration of menses) were obtained prior to regimes and not an aspect of normal ovarian physiology. While following LH down-regulation with the GnRH agonist buserelin. exposure followed by cervical dislocation. Dispersion and culture of the pituitary cells was carried out as described in Fowler et al. (Fowler et al., 1994) and only preparations with Ͼ75% viability of follows: 200 µl of fresh SFDM was added, together with the treatments made up to 25 µl with SFDM. All the culture plates contained at least 12 control wells receiving SFDM only. After 24-h incubation with the test substances, the medium was replaced and the wells were surgery. Samples were only collected from women giving a history then treated with 0.1 µmol/l GnRH (Fertagyl: Intervet UK Ltd, of regular cycles and surgery was performed at random stages of the Cambridge, UK) in 50 µl of SFDM. In all dishes, eight wells cycle. Following inspection of the tissue by a pathologist, ovaries previously exposed to SFDM received GnRH alone while four were transported to the laboratory on ice. wells previously exposed to SFDM received 50 µl of SFDM instead Individual follicles were microscopically dissected intact from the of the 50 µl of GnRH challenge. These acted as controls for the surrounding stroma in 14 pairs of ovaries. Patient details are shown magnitude of the GnRH response. Cultures were terminated after 4 h in Table I . Follicles were dissected cleanly from adhering stromal incubation by collecting the media, which was stored at -20°C for tissue to allow for accurate assessment of diameter using callipers. subsequent measurement of GnRH-induced LH as an index of GnSAF The fluid was then aspirated with a fine gauge needle and centrifuged bioactivity. The QC follicular fluid was added to each bioassay at 1, to remove cellular debris. Samples were then frozen immediately 5 and 25 µl/well, in at least four wells/dose/separate culture, to act prior to use. A total of 35 follicles were collected, covering the range as a GnSAF quality control. 3-25 mm. To produce adequate volumes for bioassay, hormone measurement and samples reliably representative of each size range, Hormone assays fluids were pooled into eight groups according to size as shown in Table II . Follicular fluid from between two and 10 follicles was
Concentrations of LH in cell-conditioned media from rat anterior pituitary cell cultures were determined using a homologous timepooled to obtain each sample for follicles up to 15 mm in diameter, the number in each group falling with increased size due to the resolved fluoro-immunoassay (DELFIA) in which rat LH was labelled with europium instead of 125 I and the assays were performed in scarcity of larger follicles in ovaries collected at random stages of the menstrual cycle. As far as possible samples were pooled evenly microtitre plates. In other respects, the assay closely followed our existing rat radioimmunoassay . Sensitivity and from the range of patients so as to minimize differences between pools in terms of patient age and indication for surgery. Only two intra-assay and inter-assay coefficient of variation (CV) values were: 0.2 ng LH/ml (NIDDK-rLH-RP3) using NIDDK-anti-rLH-S11 and well-characterized preovulatory follicles were obtained intact during the 2 year collection period and so these were assayed as single 5.4 and 7.9% respectively. Activin-A was measured using a two-site ELISA previously described (Knight et al., 1996; , samples due to the rarity of this fluid and consequently the novel nature of the data.
1996) in which follistatin does not interfere. This assay has a sensitivity of 50 ng recombinant human activin-A/L (gift from Quality control (QC) follicular fluid Genentech Inc., San Francisco, CA, USA) and mean intra-and interassay CVs of 5.0 and 9.1% respectively. The recombinant human All protocols employing human subjects were given Joint Ethical Committee Approval at Aberdeen and all patients gave informed activin-A is equipotent with the proposed candidate WHO 91/626 Reference Reagent for human activin-A. Inhibin-A concentrations consent. Ovulation was induced for IVF using recombinant FSH were determined with a two-site ELISA previously described related to follicle size, these data clearly show a size-related (Muttukrishna et al., , 1995 with a sensitivity of 2 ng recomdecrease in concentrations of GnSAF bioactivity in follicular binant human inhibin-A/L (a gift from Dr M.Rose, NIBSC, Potters fluid.
Bar, Herts, UK) and mean intra-and inter-assay CVs of 3.7 and 9.5% respectively. Inhibin-B was measured using a two-site ELISA Relationship between GnSAF bioactivity and inhibin or previously described (Lockwood et al., 1996; activin 1997) with a sensitivity of 12 ng recombinant inhibin-B/L (gift from Neither activin-A, nor inhibin-B showed a significant correlaGenentech Inc.) and intra-and inter-assay CVs of 6.2 and 9.5% tion with GnSAF bioactivity (Figure 2a and c derived follicular fluid . Direct comparison Relationships between variables were analysed by simple linear between the latter and the current study cannot, however, be correlation with significance established using Fischer's Z statistic.
made: firstly, because the bioassay used has evolved and The analyses were performed using the Statview 5 programme (Abacus Concepts Inc., Berkley, CA, USA). All results are presented become considerably more sensitive and secondly, due to the as means Ϯ SEM. nature of bioassays, it would be necessary to run both sets of follicular fluid in the same assay to obtain a valid comparison. Although the trends are essentially similar, the difference in
Results
GnSAF bioactivity between follicles Ͻ11 mm and Ͼ21 mm Relationship between follicle size and GnSAF bioactivity from IVF cycles appeared to be in the order of 200-fold. The current study and data on inhibins and activins (Fowler et al. , The greatest suppressive effect was exerted by follicular fluid from follicles of 5 ϩ 6 mm diameter, which reduced GnRH-1994 GnRH- , 1995 Magoffin and Jakimiuk, 1998; Lau et al., 1999) demonstrate more modest changes in follicular fluid concentrainduced LH secretion to 38 Ϯ 8% of control (control ϭ culture medium ϩ GnRH only: P Ͻ 0.001, Figure 1 ). This suppression tions of these hormones in different sized follicles. It is likely, therefore, that our current findings of a 4-fold decrease in was greater than that achieved by the QC follicular fluid and the follicular fluid from 25 mm follicles which reduced GnRHGnSAF bioactivity between 5-6 mm and 25 mm follicles from spontaneous cycles is more physiological than in the induced LH secretion to 54 Ϯ 8% (P Ͻ 0.01) and 72 Ϯ 2% (P Ͻ 0.05) of control respectively. The dose-response curves aforementioned IVF study . There has always been a concern that inhibin may account were condensed into ED 50 s in which the smaller the value, the less the amount of follicular fluid required to exert half for some or all GnSAF bioactivity (Culler, 1992 ). In the current study, the lack of relationship between GnSAF bioactivity and the maximal effect of the QC follicular fluid and therefore the greater the concentration of GnSAF bioactivity. These values inhibin-A, inhibin-B or activin-A in follicular fluid from this large range of follicle sizes is clear evidence that these are shown in Table III , which clearly demonstrates that small follicles, particularly those between 5 and 10 mm in diameter, hormones do not account for observed GnSAF bioactivity. This is in agreement with earlier findings, including our contain higher follicular fluid concentrations of GnSAF. The lowest ED 50 was for follicular fluid from follicles 5 ϩ 6 mm investigation of GnSAF bioactivity in follicular fluid aspirated during spontaneous cycle IVF , studies in diameter which contained significantly higher concentrations of GnSAF bioactivity than both follicles of 11 mm or over utilizing inhibin antiserum (Byrne et al., 1995) and the study by Kita et al. (Kita et al., 1994) showing no relationship and the QC follicular fluid from IVF cycles (P Ͻ 0.05-0.001).
Since maximal inhibition of GnRH-induced LH secretion was between inhibin and GnSAF in pig follicles of different sizes. Indeed, as can be seen in Figure 2 , inhibin-A appeared to FSH: raising FSH increases inhibin-B titres in the peripheral circulation within 36 h (Burger et al., 1998) . In contrast, increase with decreasing GnSAF bioactivity although this relationship was not linear due to the close clustering of the circulating inhibin-B concentrations fall sharply following GnRH antagonist administration (which reduces gonadotrophin data at the lower end of the scale. The lack of a relationship between inhibin-B and GnSAF bioactivity in the different size secretion) during the follicular phase (Welt et al., 1999) . Similarly, GnSAF bioactivity is detectable in women within follicles is more surprising. It is known that inhibin-B titres in the peripheral circulation are dependent upon the action of 8 h following FSH administration (Messinis et al., 1994) . The using follicular fluid collected during IVF cycles, and support the concept of a physiological role for GnSAF in the regulation of LH secretion during the follicular phase. Studies to determine the site of GnSAF production and the mode of regulation of GnSAF secretion by FSH are ongoing.
